

=> d his

(FILE 'HOME' ENTERED AT 12:11:43 ON 27 MAR 2002)

FILE 'BIOSIS' ENTERED AT 12:11:51 ON 27 MAR 2002

L1 6207 S METHYLENE BLUE
L2 32112 S PLASTIC
L3 90865 S ABSORB? OR ADSORP?
L4 4 S L1 AND L2 AND L3

FILE 'USPATFULL, USPAT2' ENTERED AT 12:16:08 ON 27 MAR 2002

L5 1475 FILE USPATFULL
L6 4 FILE USPAT2
TOTAL FOR ALL FILES
L7 1479 S L4
L8 8 FILE USPATFULL
L9 0 FILE USPAT2
TOTAL FOR ALL FILES
L10 8 S L1 (P) L2 (P) L3
L11 6620 FILE USPATFULL
L12 14 FILE USPAT2
TOTAL FOR ALL FILES
L13 6634 S L1
L14 64978 FILE USPATFULL
L15 102 FILE USPAT2
TOTAL FOR ALL FILES
L16 65080 S POLYVINYL CHLORIDE
L17 872 FILE USPATFULL
L18 2 FILE USPAT2
TOTAL FOR ALL FILES
L19 874 S L13 AND L16
L20 22 FILE USPATFULL
L21 0 FILE USPAT2
TOTAL FOR ALL FILES
L22 22 S L16 (P) L13

FILE 'WPIDS' ENTERED AT 12:24:00 ON 27 MAR 2002

L23 1527 S METHYLENE BLUE
L24 472896 S PLASTIC OR (POLYVINYL CHLORIDE)
L25 87 S L23 AND L24

=> log hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

48.78

75.43

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:31:15 ON 27 MAR 2002

L25 ANSWER 25 OF 87 WPIDS COPYRIGHT 2002 DERWENT INFORMATION LTD
AN 1994-135143 [16] WPIDS
DNN N1994-106265 DNC C1994-062451
TI Steam sterilisable structure for inactivating viruses - contg viral
inactivating agent with internal surface of non **PVC**
plastics material.

DC B07 D22 P31 P34
IN DEBRAUWERE, J; MATHIAS, J; PATEL, I
PA (BAXT) BAXTER INT INC
CYC 19

PI WO 9407426 A1 19940414 0199416 * EN 25p
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
W: CA JP

EP 650345 A1 19950503 (199522) EN
R: BE DE FR GB IT NL SE
JP 07503168 W 19950406 (199522)
EP 650345 A4 19950628 (199617)
EP 650345 B1 19990825 (199939) EN
R: BE DE FR GB IT NL SE
DE 69326147 E 19990930 (199946)
US 6207107 B1 20010327 (200119)

ADT WO 9407426 A1 WO 1993-US9396 19931004; EP 650345 A1 WO 1993-US9396
19931004, EP 1994-900351 19931004; JP 07503168 W WO 1993-US9396 19931004,
JP 1994-509355 19931004; EP 650345 A4 EP 1994-900351 ; EP 650345
B1 WO 1993-US9396 19931004, EP 1994-900351 19931004; DE 69326147 E DE
1993-626147 19931004, WO 1993-US9396 19931004, EP 1994-900351 19931004;

US 6207107 B1 US 1992-952427 19921005

FDT EP 650345 A1 Based on WO 9407426; JP 07503168 W Based on WO 9407426; EP
650345 B1 Based on WO 9407426; DE 69326147 E Based on EP 650345, Based on
WO 9407426

PRAI US 1992-952427 19921005
AB WO 9407426 A UPAB: 19940608

Steam sterilisable structure (110,120) for inactivating viruses contains

a therapeutically effective amount of a viral inactivating agent and has an
internal surface, in contact with the agent, that is formed of a non-
PVC plastics material.

Plastics surface in contact with the agent is of
polypropylene, styrene-ethylene-butylene-styrene, polyester or
polyurethane. The structure may be a container for storing a body fluid

or

a tube connected to such a container, in which case the tube can be
secured to a **PVC** container and the tube can be of multilayer
construction the outer layer of which is of material sealable to
PVC. The agent is **methylene blue** of pH less
than 6.3.

USE/ADVANTAGE - In the collection and housing body fluids such as
blood components and treating them to inactivate pathogens which transmit
hepatitis, HIV and herpes virus. During sterilisation **methylene**
blue migrates into **PVC** container walls, reducing its
effectiveness. By making the wall lining of non-**PVC**
plastics methylene blue can be introduced into
container prior to sterilisation and without problem of maintaining
sterilisation during introduction of **methylene blue**
after sterilisation.

Dwg.2/4

ANSWER 18 OF 87 WPIDS COPYRIGHT 2002 DERWENT INFORMATION LTD

AN 1995-067094 [09] WPIDS
DNN N1995-053271 DNC C1995-029652
TI Viral inactivation of body fluid contg. **methylene blue**
- in sterile container irradiated with light of intensity and wavelength
to activate **methylene blue** while maintaining mix.
static.
DC B02 B04 D22 E13 E23 P34
IN BRATTEN, W; FOLEY, J; WOLF, L
PA (BAXT) BAXTER TRAVENOL LAB INC; (BAXT) BAXTER INT INC
CYC 18
PI WO 9502325 A1 19950126 (199509)* EN 26p
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
W: CA JP
EP 660665 A1 19950705 (199531) EN
R: AT BE DE FR GB IT NL
JP 08501807 W 19960227 (199643) 20p
EP 660665 A4 19960703 (199644)
EP 884057 A2 19981216 (199903) EN
R: AT BE DE FR GB IT NL
EP 660665 B1 19990506 (199922) EN
R: AT BE DE FR GB IT NL
DE 69418296 E 19990610 (199929)
ADT WO 9502325 A1 WO 1994-US7508 19940706; EP 660665 A1 EP 1994-923320
19940706, WO 1994-US7508 19940706; JP 08501807 W WO 1994-US7508 19940706,
JP 1995-504593 19940706; EP 660665 A4 EP 1994-923320 ; EP 884057
A2 Div ex EP 1994-923320 19940706, EP 1998-202100 19940706; EP 660665 B1
EP 1994-923320 19940706, WO 1994-US7508 19940706, Related to EP
1998-202100 19940706; DE 69418296 E DE 1994-618296 19940706, EP
1994-923320 19940706, WO 1994-US7508 19940706
FDT EP 660665 A1 Based on WO 9502325; JP 08501807 W Based on WO 9502325; EP
884057 A2 Div ex EP 660665; EP 660665 B1 Related to EP 884057, Based on
WO

9502325; DE 69418296 E Based on EP 660665, Based on WO 9502325

*PRAI US 1993-90381 19930712
AB WO 9502325 A UPAB: 19950306

Viruses in a body fluid are inactivated by forming a mixt. of the body
fluid and a therapeutically effective amt. of **methylene**
blue in a container under sterile conditions. The mixt. is
irradiated with light of a suitable intensity and wavelength for
activating the **methylene blue** for a time sufficient to
inactivate the viruses. The mixt. is held static within the container.
Also claimed is an appts. for inactivating the viruses. It comprises a
pair of light sources (202,204) with a gap (208) between them. A support
surface (232) is positioned in the gap to support a container (10) contg.
the mixt. of body fluid and **methylene blue**.


USE - The body fluid may be plasma, red blood cells, white blood
cells, leucocytes, bone marrow, platelets, semen or organs.

ADVANTAGE - By controlling the type of **plastic** from which
the container is formed, migration of **methylene blue**
into the container can be controlled and thus is all available for virus
inactivation.

Dwg.2/3

CONFLICTING CLAIMS BETWEEN: APPLICATION AND A PATENT

CHART II-B



5445,629
will be removed
when priority to
08/090381 is claimed

6207,107 will not
present app.
filed prior to
11/29/2000

*The reference patent would NOT be prior art under 35 U.S.C. 102(e) where the patent issued from an international application and the application being examined was filed on or after Nov. 29, 2000 or filed prior to Nov. 29, 2000 and voluntarily published.

For applications filed on or after November 29, 1999,
rejections under 35 U.S.C. 102(e)/103(a) should not be made or maintained if the
applicant provides evidence that the subject matter of the reference and the claimed
invention were, at the time the invention was made, owned by the same person or subject
to an obligation of assignment to the same person.

body fluid by not o/h

sealed]?

closed